These papers typically focus on how the gut microbiome affects the therapeutic response of cancer patients to ICIs (such as PD-1/PD-L1 inhibitors), including analyzing the differences in gut microbiome composition between patients who respond and do not respond to immunotherapy, how the gut microbiome regulates the host’s immune system, and how this regulation affects anti-tumor immune responses. This evidence concerns the gene CD274 and neoplasm.